Cellectar BioSciences Partners with Ionetix for Alpha-Emitting Isotope Supply
I'm PortAI, I can summarize articles.
Cellectar BioSciences Inc. has partnered with Ionetix Corporation in a multi-year agreement to secure supplies of alpha-emitting isotopes, Actinium-225 and Astatine-211, for cancer treatment development. This collaboration supports Cellectar's targeted alpha therapies, ensuring reliable isotope sources for drug development, clinical trials, and potential commercial launches. Ionetix's cyclotron technology will meet the growing demand for these isotopes as Cellectar advances its radiotherapeutic pipeline.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments